AMLX Stock Clocks Best Day Ever After Positive Trial Data, Launches $350M Offering
The capital raise comes as Amylyx prepares to move from clinical success toward potential commercialization, following the positive trial data for avexitide announced earlier today. AMLX’s Tuesday rally followed positive topline data from the late-stage LUCIDITY study of avexitide, a once-daily injection for post-bariatric hypoglycemia. H.C. Wainwright raised its price target on Amylyx to $55 … Read more